Blog

Algernon Pharmaceuticals

Press

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney Disease” for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The Company has also filed corresponding patent applications in the United States, Canada, Europe and China. The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney…

COMPASS Pathways

Press

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her executive responsibilities will be carried forward by the existing executive team. Together with George Goldsmith and Lars Wilde, Katya co-founded COMPASS Pathways in 2017, determined to bring much needed innovation to the field of mental health care. She helped oversee the growth of COMPASS and provided…

Numinus

Press

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study.  The study in Draper, Utah, is a part of COMPASS Pathway’s phase 3 program in TRD. The international program is composed of two pivotal trials, each with a long-term follow-up component. It will enroll over 800 participants, with…

Silo Pharma

Press

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.” Eric Weisblum, Chief Executive Officer of Silo Pharma Silo Pharma is advancing the development of SPU-21…

Blog

BREAKING: Kentucky To Invest in Ibogaine Treatment for Addiction

Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for addiction, most specifically ibogaine treatments for opioid addiction. Approximately $42 million will be allocated over the next seven years to develop safety protocols and to host clinical trials for ibogaine. “Ibogaine is an alkaloid derived from three plant sources” found in West African countries. “Anecdotal evidence that is a mountain high and decades wide suggests that ibogaine, within 48 to 72 hours of administration in safe, clinically-controlled conditions, resolves opioid withdrawal syndrome,” exclaimed W. Bryan Hubbard, who chairs…